The Complete Physician's Guide to Compounded Peptides (2026)

Medically authored by Dr. Mario Quiros, MD — Board-Certified Emergency Medicine & Obesity Medicine Physician | Good Hearts Health

Over the past decade, compounded peptide therapy has moved from the fringes of integrative medicine into mainstream clinical conversation. Patients reach out to me inquiring about various peptides, typically based on what they heard from friends or non clinicians on the internet and social medial. Whether it’s BPC-157 for a torn rotator cuff, Semax for brain fog, or CJC-1295 to boost growth hormone people seem willing to adopt use of “peptides” often with zero consultation with an actual clinician. For a significant stretch of time, the FDA made it illegal for compounding pharmacies to produce most of these compounds — a decision that, as of 2026, is actively being reversed.

This post is a rigorous, honest, and complete look at the 14 peptides currently at the center of this regulatory shift. We will cover where they came from, what the science actually shows, what the real risks are, why the FDA never approved them, and what physicians should know before prescribing them if compounding access is restored.

Part I: The History of Peptide Therapy in the United States

What Are Peptides?

Peptides are short chains of amino acids — the same building blocks that make up proteins, but linked in sequences typically fewer than 50 amino acids long. Your body naturally produces thousands of them: insulin, oxytocin, glucagon, and GLP-1 are all peptides. What makes synthetic peptides therapeutically interesting is the possibility of mimicking, amplifying, or modulating specific biological signals with a relatively targeted mechanism of action.

The FDA has approved dozens of peptide-based drugs: semaglutide, tirzepatide, insulin, oxytocin, and many oncology biologics are all peptide derivatives. The concept is not fringe — it’s the specific compounds, the lack of clinical trial data, and the compounding pharmacy context that create the regulatory friction.

The Rise of Compounded Peptide Therapy

Compounding pharmacies in the United States operate under Section 503A and 503B of the Food, Drug, and Cosmetic Act, which allow licensed pharmacies to prepare customized drug preparations for individual patients based on a physician’s prescription. Throughout the 2010s, a growing market of compounding pharmacies began producing peptides nominated for the FDA’s 503A Bulk Drug Substances list but not yet formally evaluated. Under the FDA’s interim enforcement policy, substances under active evaluation fell into Category 1 — not formally authorized, but not actively prohibited either. This gray zone created a booming market, with physicians at concierge practices, anti-aging centers, and functional medicine clinics prescribing compounded peptides for recovery, cognitive performance, immune modulation, and longevity support.

September 2023: The FDA’s Category 2 Classification

In September 2023, the FDA moved 19 widely used compounded peptides into Category 2 — the designation reserved for substances the agency determined raise significant safety concerns. The FDA cited three rationale: immunogenicity concerns, manufacturing impurity risks, and insufficient human clinical trial data. The effect was immediate: compounding pharmacies were legally required to stop producing and dispensing these peptides. Industry groups and legal scholars pushed back, arguing the FDA had bypassed its own advisory committee process. Lawsuits were filed challenging the legality of the Category 2 designations.

2026: A Regulatory Turning Point

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on The Joe Rogan Experience that the administration would take steps to move approximately 14 of the 19 Category 2 peptides back to accessible status. On April 15, 2026, the FDA formally announced removal of 12 peptides from Category 2 — not because the agency affirmatively cleared them, but because their original nominations were withdrawn. The FDA simultaneously scheduled Pharmacy Compounding Advisory Committee (PCAC) meetings for July 23–24, 2026 and before end of February 2027 to evaluate whether these peptides should be formally authorized for compounding.

Critical caveat: Removal from Category 2 does not authorize compounding pharmacies to produce these peptides. It removes the explicit prohibition but they remain in a regulatory gray area until PCAC completes its review and the FDA takes formal action. As of June 2026, no peptide discussed in this post is FDA-approved for compounding or human use in the United States.

Part II: A Peptide-by-Peptide Scientific Review

For each of the 14 peptides below, I’ve organized information across four areas: proposed use and mechanism of action, efficacy evidence (human data first, animal data where human data is absent), theoretical risks, and documented adverse events. We will review where the evidence is strong, where it’s weak, and where it’s essentially absent.

Peptide	Primary Proposed Use	Best Evidence Level	Key Risk
BPC-157	Tissue/tendon repair, gut healing	3 small human pilot studies	Theoretical angiogenic cancer risk
TB-500	Wound healing, muscle/tendon repair	Related molecule human trials	Angiogenic cancer risk, WADA prohibited
MOTS-c	Metabolic health, insulin sensitivity	Limited human observational data	Broad AMPK pathway effects
KPV	Inflammatory bowel disease	Animal models only	Immune suppression with chronic use
Epitalon	Anti-aging, telomere support	Non-RCT Russian cohort studies	Telomerase activation / theoretical cancer risk
Semax	Neuroprotection, cognitive function	Russian prescription drug (30 yrs)	Dopamine/serotonin modulation effects
DSIP	Sleep quality, insomnia	Small double-blind human studies	Multi-system neurotransmitter effects
LL-37	Antimicrobial, wound healing	Human ex vivo & topical data	Dose-dependent cytotoxicity
DiHexa	Cognitive enhancement, synaptogenesis	Animal models only — no human data	HGF/c-Met oncogenic pathway activation
PEG-MGF	Muscle repair, sarcopenia	Animal models only	Anti-PEG antibodies, IGF-1 cancer risk
Melanotan II	Tanning, erectile dysfunction	Human clinical trials (tanning, ED)	Melanoma risk — highest risk compound on list
GHK-Cu	Skin/wound healing, regeneration	Small human skin studies (topical)	Copper toxicity (injectable form)
CJC-1295	GH/IGF-1 elevation, body composition	Randomized placebo-controlled trials	Long-term IGF-1 elevation and cancer risk
Ipamorelin	GH secretagogue, GI motility, anti-aging	Phase I & II clinical trials	Long-term GH/IGF-1 elevation risk

1. BPC-157 (Body Protection Compound-157)

Proposed Use & Mechanism: BPC-157 is a synthetic pentadecapeptide derived from a protein found in human gastric juice, studied primarily for regenerative and cytoprotective properties. Proposed applications include musculoskeletal injury repair, gut healing, and neuroprotection. It operates through multiple mechanisms: up-regulation of VEGFR2 and EGF receptors promoting angiogenesis, modulation of the nitric oxide system, enhancement of fibroblast activity and collagen synthesis, and interaction with dopaminergic and serotonergic CNS pathways.

Human Evidence: Three small pilot studies exist. A 12-patient knee osteoarthritis study reported 91.6% achieved significant pain reduction with intra-articular BPC-157. A 12-patient interstitial cystitis study found complete symptom resolution in 10 patients and 80% improvement in the remaining 2. A Phase I pharmacokinetics/safety study in healthy volunteers reported no adverse events. These are pilot studies with no control arms — not randomized controlled trials.

Animal Evidence: Among the most extensively studied compounded peptides in preclinical models. Rodent studies demonstrate accelerated tendon healing, bone repair, intestinal anastomosis healing, nerve regeneration, and organ protection during ischemia-reperfusion injury.

Risks & Adverse Events: Theoretical angiogenic risk in patients with occult malignancy. No serious adverse events reported in published human studies. BPC-157 has a half-life under 30 minutes with hepatic metabolism and renal clearance — limiting systemic accumulation. The absence of documented harm reflects absence of large-scale study, not confirmed safety.

2. TB-500 (Thymosin Beta-4 Analog)

Proposed Use & Mechanism: TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), one of the most abundant intracellular proteins in mammalian cells. N-terminal acetylation enhances its biological stability. Proposed uses include wound healing, tendon repair, and cardiac protection. It regulates actin dynamics to promote cell migration, stimulates angiogenesis, reduces inflammatory cytokines, and activates skeletal muscle satellite cells.

Human Evidence: No direct TB-500 human trial data. Related molecules RGN-259 (Tβ4 for dry eye disease) and RGN-137 (chronic wounds) have been studied in FDA-registered trials with positive results, providing indirect mechanistic support. Full-length Tβ4 for cardiac repair after MI has produced mixed human results.

Animal Evidence: Rodent and large-animal studies show accelerated wound healing, reduced post-MI scarring, nerve regeneration, and tendon repair. TB-500 is prohibited by WADA, indicating recognition of its performance-enhancement potential.

Risks & Adverse Events: Angiogenic mechanism creates theoretical cancer concern in patients with pre-malignant lesions. Potential autoimmune effects from immune cell migration modulation. No peer-reviewed serious adverse events in humans documented. No long-term safety data exists.

3. MOTS-c

Proposed Use & Mechanism: MOTS-c is unique: it is encoded by the mitochondrial genome, not nuclear DNA. This 16-amino-acid peptide is released from mitochondria under metabolic stress and targets skeletal muscle to improve insulin sensitivity, reduce obesity, and potentially slow aging-related metabolic decline. It activates the AICAR-AMPK signaling pathway — the cellular energy sensor that drives fat oxidation and improves glucose uptake — producing effects that partially mimic cellular exercise responses.

Human Evidence: Observational data showing significantly lower MOTS-c plasma levels in obese adolescents vs. lean controls. Cohort study in adult men found plasma MOTS-c negatively correlated with fasting insulin, HbA1c, and BMI. MOTS-c is one of the first mitochondrial-encoded peptides to enter early clinical trials; large RCTs are not yet available.

Animal Evidence: Robust. Mice receiving MOTS-c showed resistance to diet-induced obesity, improved glucose uptake, and enhanced physical endurance. Older mice demonstrated physical performance improvements comparable to younger animals.

Risks & Adverse Events: Broad AMPK pathway effects across all tissues. Theoretical mTOR suppression at high doses could interfere with muscle protein synthesis. Blood glucose monitoring warranted for patients on hypoglycemic agents. No documented human adverse events.

4. KPV (Lys-Pro-Val)

Proposed Use & Mechanism: KPV is a tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone. It retains anti-inflammatory properties while lacking melanocyte-stimulating effects. Primary proposed application: inflammatory bowel disease (Crohn’s, ulcerative colitis). KPV suppresses NF-κB — the master inflammatory gene regulator — reduces pro-inflammatory cytokines, and is selectively transported into intestinal epithelial cells via PepT1, a transporter up-regulated during intestinal inflammation. This creates a degree of site-specific delivery that is pharmacologically elegant.

Human Evidence: None. No completed human clinical trials published as of 2026.

Animal Evidence: Multiple well-designed rodent colitis models show KPV reduces intestinal inflammation markers, preserves colon length, and suppresses mucosal cytokine expression. PepT1-mediated uptake has been validated in cell line and animal studies.

Risks & Adverse Events: Theoretical immune suppression with chronic use (similar risk pattern to biologics). Mild injection-site reactions and GI changes from community self-reporting. No formally documented adverse events.

5. Epitalon (Epithalon)

Proposed Use & Mechanism: Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) from Russian gerontology research. Its central proposed mechanism is telomerase activation — reactivating the enzyme that rebuilds telomeres, which naturally shorten with each cell division and are widely regarded as markers of cellular aging. It also regulates pineal gland function, supporting melatonin production and circadian rhythm normalization.

Human Evidence: Khavinson’s group published multi-year cohort data in older Russian populations showing associations with improved physiological markers and reduced all-cause mortality in one 12-year follow-up study. However, these were not blinded RCTs and have not been independently replicated in Western peer-reviewed literature with modern trial designs.

Animal Evidence: Telomerase activation and telomere elongation confirmed in fruitfly, rodent, and cell-line studies. Extended lifespan observed in some animal models. A 2025 cell-line study confirmed telomerase activation in human somatic cells.

Risks & Adverse Events: The telomerase-cancer question is the critical concern. Telomerase activation is a hallmark of cancer cell biology — most cancers achieve immortality by upregulating telomerase. Administering a telomerase-activating compound to patients with occult pre-malignant cells carries theoretical cancer acceleration risk. Community-reported side effects include injection-site irritation, fatigue, vivid dreams, headache, and mild nausea. No formally documented serious adverse events.

6. Semax

Proposed Use & Mechanism: Semax is a synthetic heptapeptide derived from ACTH(4-10) and is a registered prescription medication in Russia for stroke recovery and cognitive disorders — giving it more real-world clinical history than most compounds on this list. It has been engineered to eliminate steroidogenic activity (it does not stimulate cortisol release). Mechanisms: upregulation of BDNF and NGF, modulation of dopaminergic and serotonergic systems, neuroprotection against hypoxia and glutamate excitotoxicity, and inhibition of enkephalin degradation.

Human Evidence: Russian-language clinical publications document controlled use in stroke rehabilitation and cognitive impairment with positive outcomes. The 30-year Russian prescription history provides a substantial absence-of-catastrophic-harm signal, though Western RCT replication is limited.

Animal Evidence: Reduced infarct volume in stroke models, improved spatial memory, and protection against glutamate neurotoxicity across multiple rodent studies.

Risks & Adverse Events: Theoretical psychiatric risks in patients with history of mania, psychosis, or bipolar disorder. Nasal irritation and mucosa discoloration with intranasal use are the most commonly reported side effects. No serious adverse events documented in available literature.

7. DSIP (Delta Sleep-Inducing Peptide / Emideltide)

Proposed Use & Mechanism: DSIP is a naturally occurring nonapeptide first isolated in 1977. It is a sleep-promoting substance rather than a sedative — it modulates sleep architecture toward deeper stages rather than simply causing drowsiness. Acts on serotonin, glutamate, dopamine, and melatonin systems, enhances delta-wave EEG activity, and stimulates pituitary LH and GH release.

Human Evidence: Mixed. One double-blind study in chronic insomniacs showed significant improvements in sleep duration and quality with IV DSIP vs. placebo. A separate double-blind RCT found effects were weak and partly attributable to placebo group variation, concluding short-term DSIP was “not likely to be of major therapeutic benefit” as a standalone insomnia treatment. Evidence base is small and clinical signal is not robust.

Animal Evidence: Consistent sleep-promoting effects in multiple species. DSIP-treated rodents show increased delta-wave sleep time and neurotransmitter profiles consistent with deeper sleep stages. A 2024 murine study demonstrated efficacy in an insomnia model.

Risks & Adverse Events: Multi-system neurotransmitter effects create theoretical mood disruption and HPA axis modulation risks with chronic use. Short in vivo half-life limits accumulation. No documented serious adverse events in published human studies.

8. LL-37

Proposed Use & Mechanism: LL-37 is the only cathelicidin antimicrobial peptide identified in humans — a 37-amino-acid host defense peptide released from neutrophils and epithelial cells during infection. Proposed therapeutic uses: drug-resistant bacterial infections (MRSA, VRE), wound healing, and immune support. Mechanisms: disrupts microbial cell membranes, binds and neutralizes LPS and LTA (the molecular triggers of septic shock), suppresses macrophage pyroptosis in sepsis, enhances neutrophil extracellular traps, and promotes epithelial wound healing.

Human Evidence: Demonstrated bactericidal activity against drug-resistant pathogens including MRSA and VRE in human tissue and ex vivo models. Topical wound healing studies show clinical promise. Full controlled human trial evidence for systemic administration remains limited.

Animal Evidence: In murine sepsis models, LL-37 significantly improved survival by suppressing macrophage pyroptosis and enhancing antimicrobial responses. Anti-biofilm activity demonstrated in animal wound models.

Risks & Adverse Events: Dose-dependent cytotoxicity to human cells at elevated concentrations (the same mechanism that kills bacteria can damage host cells). Rapid degradation in biological fluids limits systemic exposure but complicates delivery. Complex relationship with certain cancers — some studies show anti-cancer effects, others show elevated LL-37 associated with tumor growth. Toxicity testing of a derivative showed no systemic toxicity in rats.

9. DiHexa

Proposed Use & Mechanism: DiHexa is a synthetic hexapeptide developed at Washington State University, originally derived from angiotensin IV. Its defining proposed mechanism is synaptogenesis — the formation of new synaptic connections between neurons. It works through the HGF/c-Met signaling pathway, potentiating Hepatocyte Growth Factor activity to promote neuronal survival and synapse formation. Preclinical data shows it may be up to 10 million times more potent than BDNF in driving synapse formation in certain models. It crosses the blood-brain barrier efficiently.

Human Evidence: None published. DiHexa has not been studied in any human clinical trial. Its entire evidence base is preclinical.

Animal Evidence: Rodent models of cognitive impairment show substantial improvement in spatial memory tasks. Critically, DiHexa did not improve cognition in animals with normal function — effects appear specific to states of impairment or neurodegeneration, not general enhancement.

Risks & Adverse Events: The HGF/c-Met pathway plays regulatory roles in liver, kidney, epithelial tissues, and is involved in tumor invasion and metastasis in certain cancers — raising significant mechanistic oncogenic concern. Unknown dose-response safety window given extraordinary potency. Anecdotally reported: anxiety, agitation, insomnia at higher doses. This is the compound I approach with the most clinical caution on this list, given its potency and complete absence of human safety data.

10. PEG-MGF (Pegylated Mechano Growth Factor)

Proposed Use & Mechanism: PEG-MGF is a chemically modified splice variant of IGF-1 that is locally expressed in skeletal muscle in response to mechanical load. Pegylation (attachment of polyethylene glycol chains) extends its plasma half-life from minutes to days. Proposed uses: skeletal muscle repair, recovery from injury, and muscle-wasting conditions. Mechanisms include activation of muscle satellite cells, enhancement of macrophage and neutrophil recruitment to injury sites, and stimulation of protein synthesis in recovering muscle fibers.

Human Evidence: None. No published human clinical trials of injected PEG-MGF exist.

Animal Evidence: Rodent studies show accelerated recovery from surgically induced muscle injuries, reduced inflammatory infiltrate, and promotion of satellite cell proliferation.

Risks & Adverse Events: As an IGF-1 splice variant, theoretical cancer promotion risk applies. Anti-PEG antibodies can develop with repeated administration of pegylated compounds, causing accelerated clearance or, rarely, hypersensitivity reactions. No controlled human adverse event data exists.

11. Melanotan II

Proposed Use & Mechanism: Melanotan II is a non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R) developed at the University of Arizona as a cosmetic tanning agent. It also acts as a potent erectile dysfunction treatment and appetite suppressant through hypothalamic MC4R activation. Proposed uses: cosmetic tanning, erectile dysfunction, and appetite suppression.

Human Evidence: Has the most human clinical trial data of any compound on this list. Studies in over 100 subjects confirmed dose-dependent effective tanning with subcutaneous administration. MT-II was also shown to be a potent inducer of penile erection — a serendipitous finding that led to development of bremelanotide (PT-141), which is now FDA-approved as Vyleesi for female sexual dysfunction.

Animal Evidence: Extensively studied. Tanning, anorexia, erectile, and metabolic effects are well-established across multiple species.

Risks & Adverse Events: This is the highest-risk compound on this list for patients with melanoma risk factors. MC1R activation accelerates melanin production in all melanocytes — including atypical ones. At least five published case reports of melanomas during or after MT-II use exist, all in individuals with additional risk factors. Eruptive dysplastic nevi (sudden appearance of multiple atypical moles) documented following MT-II use. Darkening of existing moles occurs within weeks of starting MT-II. Other adverse events: nausea (majority of subjects), facial flushing, spontaneous prolonged erections, and hypertension. The FDA has issued multiple warning letters against MT-II vendors.

Clinical Note: Any patient with personal or family history of melanoma, numerous atypical moles, or significant UV exposure history should not use Melanotan II under any circumstances.

12. GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper)

Proposed Use & Mechanism: GHK-Cu is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973. Its plasma concentration declines significantly with age. Proposed as a regenerative agent for wound healing, skin rejuvenation, hair growth, and anti-inflammatory effects. Notably, it was removed from Category 1 (not Category 2) in the April 2026 FDA action — the concern was specifically about the injectable form. Mechanisms: stimulation of collagen, elastin, and glycosaminoglycan synthesis; promotion of angiogenesis; activation of over 31 tissue repair genes; antioxidant activity via copper-mediated superoxide dismutase enhancement.

Human Evidence: Three small human skin quality studies (~30 subjects total) showed improvements in skin firmness, elasticity, and photoaging markers with topical GHK-Cu. No serious adverse events reported. A critical limitation: standard topical application results in virtually no GHK-Cu penetrating intact human skin — making injectable forms more pharmacologically relevant but more poorly studied.

Animal Evidence: Robust animal wound healing data showing accelerated closure, improved tensile strength, and reduced scarring.

Risks & Adverse Events: Long history of safe topical cosmetic use. Systemic copper toxicity is theoretically possible with injectable forms at high doses. Injectable risk profile is essentially unstudied.

13. CJC-1295

Proposed Use & Mechanism: CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) with one key modification: it selectively and covalently binds to endogenous albumin after subcutaneous injection, extending its half-life from minutes to 6–10 days (DAC version). This dramatically prolongs GH and IGF-1 stimulation. Almost exclusively used with Ipamorelin for synergistic, physiologically pulsatile GH release. Proposed uses: age-related GH decline, body composition improvement, recovery, sleep quality, and anti-aging.

Human Evidence: Among the strongest evidence of any compound on this list. Two randomized, placebo-controlled, double-blind, ascending-dose trials in healthy adults (ages 21–61) showed dose-dependent 2- to 10-fold GH increases lasting 6+ days after a single injection, and 1.5- to 3-fold IGF-1 increases lasting 9–11 days. Described as “safe and relatively well tolerated” with no serious adverse reactions at doses studied.

Animal Evidence: Normalized growth in GHRH knockout mice, validating its pharmacological mechanism.

Risks & Adverse Events: Most significant long-term concern: sustained IGF-1 elevation above physiological ranges is associated epidemiologically with increased colorectal and breast cancer risk. Fluid retention, acromegalic features at excessive doses, glucose intolerance, and exacerbation of IGF-1-driven conditions are additional concerns. Published adverse events in trials: transient headache, dizziness, flushing, water retention. No serious adverse events. Trials were 28–49 days — insufficient to assess long-term cancer risk.

14. Ipamorelin

Proposed Use & Mechanism: Ipamorelin is a synthetic pentapeptide and selective ghrelin receptor (GHSR-1a) agonist — originally developed by Novo Nordisk. It was the first GHRP recognized for its selectivity: it stimulates GH release with specificity similar to GHRH while producing significantly lower effects on ACTH, cortisol, and appetite than older GHRPs (GHRP-6, GHRP-2). Almost universally co-prescribed with CJC-1295 for synergistic GH release.

Human Evidence: Multiple Phase I and Phase II clinical trials. Phase II data for post-operative ileus showed significantly reduced time to GI recovery vs. placebo after bowel surgery. GH-secretagogue effects confirmed in healthy volunteers. One of the better-characterized GHS peptides in terms of clinical pharmacokinetics and safety data.

Animal Evidence: Well-established GH secretory profiles, dose-response relationships, and selectivity data across multiple species, reflecting its Novo Nordisk pharmaceutical origin.

Risks & Adverse Events: Same long-term GH/IGF-1 elevation concerns as CJC-1295. Its selectivity advantage means cortisol and appetite effects are minimal compared to older GHRPs. Clinical trial adverse events: mild, comparable to placebo. No serious adverse events attributed to Ipamorelin across published trial data. No long-term safety data beyond trial duration (typically 4–16 weeks).

Part III: Why None of These Peptides Are FDA Approved

What FDA Approval Actually Means

The FDA drug approval process exists for good reasons rooted in the most consequential pharmaceutical disasters in modern medical history. The thalidomide tragedy — in which a drug prescribed to pregnant women for morning sickness caused severe birth defects in thousands of infants — was the galvanizing event that established modern clinical trial requirements in the United States.

When a drug receives FDA approval, it means the following has occurred:

Preclinical studies characterized toxicity, dose-response, and preliminary efficacy in laboratory and animal models
Phase 1 clinical trials in healthy human volunteers established safety, pharmacokinetics, and appropriate dosing
Phase 2 clinical trials in patients with the target condition assessed efficacy signals and continued safety monitoring
Phase 3 clinical trials in hundreds to thousands of patients confirmed efficacy, compared the drug to existing treatments, and comprehensively characterized safety
FDA NDA review evaluated all accumulated data and determined that benefits outweigh known and potential risks for the intended population
Post-market surveillance continues monitoring for new safety signals for the life of the drug

FDA approval is not a guarantee of perfect safety — post-approval signals emerge for many drugs. But it is a meaningful guarantee that known risks have been systematically characterized and weighed against documented benefits. For unapproved compounds, none of those characterizations exist.

Why These Peptides Haven’t Gone Through FDA Approval

The path to FDA approval is expensive and long. Conservative estimates put the average cost at over $1 billion USD with timelines of 10–15 years — an investment only viable if a patent allows market exclusivity to recoup costs.

Most of the peptides on this list present a fundamental economic challenge: many are naturally occurring or structurally simple enough that they cannot be patented in their base form. If any pharmaceutical company spent a billion dollars proving BPC-157 works for tendon healing, a competitor could immediately produce and sell the same compound at a fraction of the cost. There is no return on investment. This is what pharmacologists call the “funding gap” for non-patentable compounds — a structural reality of how drug development is financed in the United States, not a conspiracy.

Additionally, Semax and Epitalon were developed in the former Soviet Union, where clinical trial standards and publication practices differ substantially from FDA requirements. The data exists but doesn’t meet the FDA’s evidentiary standards.

What the Lack of Approval Means for Patients

No validated dosing: No Phase 1 or Phase 2 trial has established safe and effective dose ranges for most of these compounds. Doses used clinically are empirical.
No manufacturing oversight: Compounded preparations are not subject to the same cGMP standards as FDA-approved drugs. Purity, potency, and sterility are not independently validated.
Unknown drug interactions: Without systematic study, interactions with a patient’s other medications are unknown.
No established contraindications: Patient populations for whom these peptides might be harmful have not been formally characterized.
No post-market safety monitoring: There is no formal adverse event reporting system for unapproved compounded peptides.

Part IV: Why Patients Are Using These Compounds Anyway — And What Physicians Should Do

Understanding the Patient Demand

It would be easy — and wrong — to dismiss the millions of Americans using compounded peptides as simply misinformed. Several legitimate forces are driving patient adoption, and physicians who dismiss them will lose the therapeutic relationship precisely when patients need guidance most.

The first is a genuine unmet need. Conventional medicine has limited tools for musculoskeletal injury recovery, cognitive decline, age-related hormone changes, and autoimmune gut conditions. When a patient with a chronic tendon injury reads that BPC-157 accelerated healing in every rodent model it’s been tested in, and no physician has offered anything beyond “rest and physical therapy,” the calculus of trying a potentially helpful compound is not irrational. It may be premature. But it isn’t irrational.

The second is the wellness culture and influencer effect. Longevity and optimization dominate consumer health media. When a physician on a major podcast describes their own peptide use and reports meaningful benefit, the credibility transfer is powerful — regardless of what the controlled trial literature shows.

The third is the gray market problem created by the 2023 ban. When the FDA moved 19 peptides to Category 2, it didn’t eliminate demand — it eliminated legal supply. Patients who had experienced subjective benefit migrated to unregulated online vendors with zero pharmaceutical oversight, unknown purity, and no quality control. The irony is that the 2023 action may have made patients less safe by pushing them from pharmacist-compounded preparations to Chinese peptide suppliers with no accountability whatsoever.

How Physicians Should Approach Prescribing if Compounding Is Restored

If the PCAC process results in formal authorization of some or all of these peptides for compounding, physicians will face real clinical decisions. Here is my framework:

1. Screen Before You Prescribe

Every patient should be screened for conditions that elevate risk. Personal or family history of cancer is relevant to all peptides with angiogenic or growth-promoting mechanisms (BPC-157, TB-500, PEG-MGF, CJC-1295/Ipamorelin, Epitalon). History of melanoma or atypical moles is an absolute precaution with Melanotan II. Active autoimmune disease is relevant to LL-37 and KPV. Diabetes or pre-diabetes warrants monitoring with MOTS-c, CJC-1295, and Ipamorelin. Psychiatric history is relevant to Semax, DSIP, and DiHexa. Pregnancy: all compounds should be avoided — no safety data exists.

2. Use Compounding Pharmacies With Verifiable Standards

Sourcing from PCAB-accredited compounding pharmacies with documented USP 795/797 compliance and independent third-party testing is the minimum acceptable standard. A valid prescription to an unregulated online vendor is not ethically equivalent to a prescription to a quality compounding pharmacy.

3. Document Informed Consent Explicitly

Patients should understand in writing that these compounds are not FDA-approved, human safety and efficacy data is limited, long-term effects are unknown, and they are participating in what is effectively early-access clinical use. This respects patient autonomy and ensures decisions are genuinely informed.

4. Monitor Appropriately

Growth hormone secretagogues (CJC-1295, Ipamorelin) warrant baseline and periodic IGF-1 monitoring. Metabolically active peptides require baseline and follow-up metabolic panels. Any change in moles or pigmentation during Melanotan II use requires immediate dermatology referral. Patients with anxiety or depression history on Semax or DiHexa should be monitored for mood changes.

5. Set Honest Expectations

The honest clinical conversation is: we have reason to think this might help, some animal or early human data is encouraging, but we do not have the same level of evidence we would require before prescribing metformin or lisinopril. If you understand that and are willing to proceed with monitoring, I am willing to prescribe it. That conversation is more useful to patients than either reflexive refusal or uncritical enthusiasm.

Dr. Q’s Take

Most of these peptides are operating in an evidential space between “very promising” and “well established.” A few — CJC-1295, Ipamorelin, and Semax — have genuine controlled human data. Others — DiHexa, PEG-MGF — are essentially laboratory compounds being used in humans with no clinical trial evidence at all. The risks are not all equal, and the evidence is not all equal.

What I am confident about: the 2023 FDA ban did not make patients safer. It made them less safe by removing regulated compounding pharmacies from the equation and pushing demand toward an uncontrolled gray market. If the PCAC process results in formal authorization of some of these compounds for compounding, that represents a meaningful improvement in patient safety — not because the compounds are suddenly proven safe, but because pharmaceutical-grade production, physician oversight, and proper informed consent are better than a peptide vial shipped from overseas with no quality assurance.

The right answer is not to dismiss patients who want these therapies, and it is not to prescribe them without hesitation. The right answer is to be the physician who actually knows the evidence — including its limits — and who can have an honest conversation about what we know, what we don’t, and what responsible use looks like. That’s the conversation I try to have in my practice every day.

Questions About Peptide Therapy or Wellness Medicine?

At Good Hearts Health, I offer personalized concierge medicine consultations that include evidence-based discussions of emerging therapies, hormonal optimization, and GLP-1 weight loss care. If you want to understand your options with a physician who actually knows the science, I’d love to hear from you.

Book a consultation with Good Hearts Health →

References & Further Reading

Medically Authored by Dr. Mario Quiros, MD. Board-Certified Emergency Medicine and Obesity Medicine Physician. Owner and Operator of Good Hearts Health. This article is for educational purposes only and does not constitute medical advice. Consult your physician before starting any new therapy.